Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 21.14% | -296.19% | -241.41% | -236.42% | -69.14% |
| Total Depreciation and Amortization | 17.86% | 20.90% | 14.78% | 4.90% | -6.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.86% | 3,018.05% | 1,207.16% | 1,358.82% | 451.74% |
| Change in Net Operating Assets | 57.49% | 26.47% | 53.11% | -3.35% | -174.73% |
| Cash from Operations | -5.58% | 0.38% | 18.07% | 10.45% | -2.47% |
| Capital Expenditure | 2.38% | 23.08% | 7.61% | -67.70% | -84.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -245.98% | -6,794.94% | -642.11% | -1.77% | 168.58% |
| Cash from Investing | -263.01% | -4,719.07% | -483.06% | -5.98% | 177.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.82% | -7.27% | -9.26% | -9.43% | -5.77% |
| Issuance of Common Stock | 19.62% | 2.73% | -23.07% | 106.53% | 81.26% |
| Repurchase of Common Stock | 48.75% | -606.67% | -252.17% | 63.96% | 63.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 62.76% | -16.46% | -300.00% | -529.65% | -458.05% |
| Cash from Financing | 21.81% | 2.18% | -24.84% | 100.60% | 77.40% |
| Foreign Exchange rate Adjustments | 51.94% | 573.47% | 516.84% | 48.77% | 231.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -138.54% | -381.18% | -148.54% | 443.02% | 394.65% |